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Abstract Truncating mutations in the giant sarcomeric protein Titin result in dilated
cardiomyopathy and skeletal myopathy. The most severely affected dilated cardiomyopathy
patients harbor Titin truncations in the C-terminal two-thirds of the protein, suggesting that
mutation position might influence disease mechanism. Using CRISPR/Cas9 technology, we
generated six zebrafish lines with Titin truncations in the N-terminal and C-terminal regions.
Although all exons were constitutive, C-terminal mutations caused severe myopathy whereas N-
terminal mutations demonstrated mild phenotypes. Surprisingly, neither mutation type acted as a
dominant negative. Instead, we found a conserved internal promoter at the precise position where
divergence in disease severity occurs, with the resulting protein product partially rescuing N-
terminal truncations. In addition to its clinical implications, our work may shed light on a long-
standing mystery regarding the architecture of the sarcomere.
DOI:10.7554/eLife.09406.001
Introduction
The use of genetics in clinical medicine depends on knowledge that an identified mutation confers
risk of disease. Recent guidance issued by the American College of Medical Genetics emphasizes
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that the strongest form of evidence supporting causality of a mutation is whether it results in a trun-
cation of the protein (nonsense, frameshift or canonical splice-site mutations), specifically for genes
where loss-of-function mutations are known to cause disease (Richards et al., 2015). Truncating
mutations within alternatively spliced exons and at the extreme C-terminus of the protein must be
interpreted with caution, as they may have little to no impact on protein function. However, the
guidelines do not address whether truncating mutations at different positions along the length of
the protein might differ in phenotype severity or mechanism of action, a finding that could compli-
cate interpretation of truncation mutations for a broad range of inherited diseases.
Truncations in the giant sarcomeric protein Titin (TTN) reveal patterns that are at odds with this
uniform assignment of causality. TTN lies along the length of the sarcomere and is thought to medi-
ate passive tension of the muscle fiber, while also serving as a binding scaffold for a large number of
proteins, including actin and myosin (Lewinter and Granzier, 2013). Individual regions of TTN are
annotated according to their localization to the Z-disc, I-band, A-band, and M-line regions of the sar-
comere visualized on immuno-electron micrographs Fu¨rst et al., 1988. Truncating and/or missense
mutations in TTN result in cardiac (dilated cardiomyopathy [DCM]) and skeletal muscle (myofibrillar
myopathy) disease (Chauveau et al., 2014). Recent estimates suggest that truncation mutations in
TTN may explain as much as 25% of DCM (Herman et al., 2012), a disease which affects upwards of
1 in 2500 individuals (Codd et al., 1989). Although truncations are found along the length of TTN in
DCM patients, in patients with the most severe forms of DCM, truncations reside within the C-termi-
nal two-thirds of the protein (from amino acid 14,760 onwards, Figure 1A), specifically in the distal I-
band and A-band (we will refer to these as C-terminal truncations) (Herman et al., 2012;
Roberts et al., 2015). Multiple TTN exons are alternatively spliced (Bang et al., 2001), with many
having little to no inclusion within cardiac isoforms, and splicing has been proposed to at least par-
tially explain the exclusion of N-terminal mutations in patients with end-stage DCM (Herman et al.,
2012). Nonetheless, over 5500 amino acids in the N-terminal region of the protein are constitutive
(percent spliced in or PSI >0.9, Figure 1B), implying the importance of other mechanisms.
eLife digest The heart is able to beat partly because of a large protein called Titin that helps to
give heart muscle its elasticity. Mutations that shorten the gene that encodes Titin can cause part of
the heart to become enlarged and weakened, a condition called dilated cardiomyopathy. Some
people with shortened copies of this protein have a mild form of cardiomyopathy and are able to
lead relatively normal lives. Others develop more severe symptoms that prevent the heart from
pumping blood effectively and may even cause the individual to need a heart transplant.
Genetic studies have revealed that mutations that shorten the Titin protein by disrupting the
portion of the gene corresponding to the latter two-thirds of the protein (which encodes the so-
called “C-terminal” end of the protein) cause more severe symptoms than mutations that occur near
the start of the gene. But it is not clear why the location of the mutation matters.
To investigate this problem, Zou et al. used a gene-editing tool called CRISPR to create
genetically engineered zebrafish. These fish had mutations at one of six different points in the gene
that encodes the zebrafish version of Titin. Just as with humans, mutations near the C-terminal end
of the gene caused more severe muscle problems in the fish.
Specifically, Zou et al. found that the worst disease was associated with mutations that occurred
at or after a “promoter” region within the gene and near this C-terminal end. Normally, the
promoter produces an independent smaller form of the Titin protein, which helps to reduce the
severity of muscle problems in zebrafish that have mutations near the start of the gene. However,
mutations near the C-terminal end of the gene also damage this smaller form, preventing this
failsafe from working, and so lead to more severe symptoms. Zou et al. also found this promoter to
be active in both mouse and human hearts.
Future work will focus on learning how this smaller form of Titin works to help muscle develop
and withstand stress and determine whether increasing its production can overcome the more
severe forms of disease.
DOI:10.7554/eLife.09406.002
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Figure 1. Generation of six stable zebrafish lines with truncating mutations in ttna, the zebrafish orthologue of TTN, using CRISPR/Cas9 technology. (A)
Schematic of the TTN meta-transcript (Ensembl ID ENST00000589042), including all known exons with the exception of the Novex-3 exon, which is
exclusive to the Novex-3 isoform (Ensembl ID ENST00000360870). Sarcomeric regions are denoted by different colors. A heatmap of PSI values
computed from RNA-Seq data of two DCM hearts is shown below the cartoon representation of the transcript. Above the schematic, amino acid
positions of truncating mutations of TTN in end stage dilated cardiomyopathy identified in a prior study (Roberts et al., 2015) are highlighted (gold
squares). We restricted our representation to nonsense, frameshift or canonical splice-site mutations and did not include predicted disruptions of
putative splice enhancers. A truncating mutation mapping to the Novex-3 exon is not shown. Below the schematic, the corresponding human amino
acid positions of zebrafish exons disrupted through CRISPR/Cas9 technology in our work are depicted, including six stable mutant lines (n1, n2, n3, c1,
c2, c3, gold diamonds) and individual exons targeted by high dose guide RNA/Cas9 injection (gold triangles). (B) Many of the exons not mutated in
end-stage DCM are constitutive (i.e. show minimal alternative splicing). Histogram representing the PSI frequency distribution for TTN amino acids N-
terminal to amino acid 14,760, which is the most N-terminal amino acid in which a definitive truncation mutation is found in an end-stage DCM patient.
The median PSI value was computed for each TTN exon using RNA-Seq datasets from hearts of two patients with DCM (GEO Accession GSM1380722,
GSM1380723).
DOI: 10.7554/eLife.09406.003
The following figure supplements are available for Figure 1:
Figure supplement 1. Domain organization of human TTN (top), zebrafish ttna (middle) and zebrafish ttnb (bottom).
DOI: 10.7554/eLife.09406.004
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Results
We sought to address the basis of this variation of severity with mutation position. For a disease
such as DCM, in which inheritance is most commonly observed as adult-onset autosomal dominant
with variable penetrance, deciphering such mechanisms in mouse models can be challenging, as het-
erozygotes tend to show minimal phenotypes and homozygotes tend to be embryonic lethal
(Gramlich et al., 2009). We selected the vertebrate zebrafish model for several reasons. Firstly,
zebrafish has high sequence conservation of sarcomeric proteins with mammals and recapitulate dis-
ease phenotypes with loss-of-function of multiple established Mendelian cardiomyopathy genes
(Dahme et al., 2009). In fact, forward genetic screens have generated zebrafish Titin mutants,
although in only one case is the position of the mutation known (Xu et al., 2002; Steffen et al.,
2007; Myhre et al., 2014). Secondly, zebrafish can live for up to two weeks with a non-contractile
heart, thus allowing mechanistic studies of homozygote mutants. Thirdly, the relatively low cost and
large clutch size of zebrafish allow the ability to generate multiple mutant lines and provide statisti-
cal power for robust conclusions.
As a result of an ancestral genome duplication event, zebrafish include two titin genes: ttna and
ttnb (Xu et al., 2002; Steffen et al., 2007; Seeley et al., 2007). Ttna shares considerable similarity
with the human TTN gene (Figure 1—figure supplement 1, showing ‘meta-transcripts’ with all pos-
sible exons included). The zebrafish and human proteins are similar in length (~32,000–35,000 amino
acids depending on the splice isoform) and share 56% identity and 82% homology. They have a
nearly identical domain organization, with three immunoglobulin-like of domains (proximal, mid, and
distal), an elastic PEVK region, N2A and N2B domains which distinguish cardiac and skeletal iso-
forms, a fibronectin-immunoglobulin repeat region that mediates binding to myosin, and a C-termi-
nal kinase domain. In both species, alternative splicing targets the middle Ig-like and PEVK domains,
which modulate passive tensile properties of the sarcomere (Granzier and Labeit, 2004). Cardiac
isoforms typically include much of this elastic region as well as the N2B ± N2A domains, while skele-
tal isoforms include the N2A domain but exclude N2B as well as much of the elastic region. Multiple
mutants isolated from forward genetic screens coupled with morpholino knockdown analysis have
demonstrated that ttna is essential for cardiac sarcomere formation in zebrafish (Xu et al., 2002;
Myhre et al., 2014; Seeley et al., 2007).
Although the paralagous zebrafish ttnb gene is dispensable for cardiac sarcomere development
(Steffen et al., 2007; Seeley et al., 2007), it plays an essential role in skeletal muscle sarcomerogen-
esis. It is expressed at comparable levels to ttna in skeletal muscle (as opposed to ~2/3 of ttna abun-
dance in heart). In contrast to human TTN or zebrafish ttna, the ttnb protein has abbreviated
versions of the middle Ig-like and PEVK elastic domains (Figure 1—figure supplement 1) and thus
more closely resembles skeletal rather than cardiac muscle isoforms of ttna. Morpholino-based skip-
ping of the N2A exon of either ttna or ttnb results in severe disruption of skeletal muscle sarcomeric
architecture, highlighting the mutual contribution of the two genes (Seeley et al., 2007).
Table 1. Characteristics of six stable zebrafish truncation mutant lines. Size of insertion/deletion, PSI
of corresponding exon in embryonic zebrafish heart and skeletal muscle, protein change using
standard nomenclature (23), and corresponding human amino acid protein for the TTN meta-
transcript are shown.
Mutant ID Mutation type
PSI of mutated exon
(heart/skeletal muscle) Zebrafish protein change#
Orthologous human
amino acid position*
n1 7bp insertion 1.000/1.000 p.E1463fsX3 1697
n2 1bp insertion 1.000/1.000 p.A2815GfsX3 3048
n3 2bp deletion 1.000/1.000 p.Q7597GfsX8 9693
c1 2bp deletion 0.996/1.000 p.E15193GfsX8 17996
c2 4bp deletion 1.000/0.995 p.T18311GfsX8 21215
c3 8bp insertion 1.000/0.996 p.A29052RfsX8 32003
#Amino acid numbering is relative to ENSDART00000109099. *Amino acid numbering is relative to TTN meta-
transcript.
DOI: 10.7554/eLife.09406.005
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Figure 2. C-terminal ttna truncations result in a severe skeletal muscle phenotype while N-terminal truncations are indistinguishable from wild-type.
Fixed heart (A) and skeletal muscle (B) samples of 72 hpf ttnawt/wt, ttnan/n and ttnac/c mutant embryos were analyzed by immunostaining for a–actinin,
which highlights Z-disc architecture. The cardiac sarcomere was disarrayed in all mutants. However, in skeletal muscle ttnac/c mutants demonstrated
severe sarcomeric disarray while ttnan/n mutants retained sarcomeric architecture. Scale bar: 10 umm. (C) All targeted TTN exons are constitutive (i.e.
not alternatively spliced) in both cardiac and skeletal muscle. PSI values computed for each mutated exon using RNA-Seq data for dissected hearts and
trunk skeletal muscle for various mutant genotypes at 72 hpf. Wild-type fish were analyzed at both 72 hpf and adulthood. Analysis was limited to
samples with a sufficient number of exon-exon junction reads to accurately estimate PSI (Pervouchine et al., 2013). (D) Nonsense-mediated decay
reduces mutant transcript levels to ~20–25% of wild-type, but does not vary substantially across mutations. Targeted RNA-Seq was used to determine
the ratio of reads derived from the mutant allele vs. the wild-type allele in ttnan/wtand ttnac/wt heterozygote mutants, which serves as an estimate of
nonsense-mediated decay efficiency.
DOI: 10.7554/eLife.09406.006
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Using CRISPR/Cas9 technology (Jinek et al., 2012), we engineered six truncating mutations
within the major cardiac TTN orthologue, ttna, (Figure 1A, Table 1), so that the resulting protein
product would be truncated at either the Z-disk (n1), proximal or mid I-band (n2 and n3) or proximal,
mid, or distal A-band (c1, c2, and c3). From wild-type (WT) zebrafish embryo transcriptome data, we
anticipated that all exons would be constitutive in both cardiac and skeletal muscle (PSI
>0.99, Table 1). Mutant lines were bred for two generations to minimize any off-target effects from
the genome editing, and we studied the F3 generation for cardiac and skeletal muscle
consequences.
As expected (Xu et al., 2002; Gramlich et al., 2015), ttna truncations showed no gross pheno-
type in heterozygotes, with all heterozygotes attaining sexual maturity. We thus focused on homozy-
gote mutants, with the expectation that partial rescue from ttnb could potentially elicit phenotypic
differences among mutants, especially in skeletal muscle where it is expressed at comparable levels
to ttna and has a documented essential role. N-terminal (ttnan1/n1, ttnan2/n2, ttnan3/n3, collectively
referred to as ttnan/n) and C-terminal (ttnac/c) truncations all showed severe deficits in cardiac con-
tractility (Video 1) and typically died within two weeks of birth. Immunostaining revealed severe car-
diac sarcomeric disarray (Figure 2A).
In contrast to their cardiac phenotypes, ttna mutants demonstrated a sharp division in develop-
ment of skeletal muscle disease. All three ttnan/n mutants were capable of grossly normal motion
while the ttnac/c truncations were entirely unable to move (Video 2). Immunostaining supported the
distinction, with ttnac/c mutants having highly distorted sarcomeric architecture while ttnan/n architec-
ture closely resembled wild-type (Figure 2B). To confirm transcription of all mutant isoforms, assess
nonsense-mediated decay, and rule out selective alternative splicing of ttnan/n mutant exons, we
performed RNA-Seq of heart (cardiac muscle) and trunk (skeletal muscle) of 3 day old embryos, as
well as adult fish. All mutated exons appeared constitutive in both heart and skeletal muscle, across
all genotypes (Figure 2C). We next examined the extent of nonsense-mediated decay (NMD) for
each mutant allele by performing targeted RNA sequencing of heterozygote embryos and compar-
ing the number of reads for wild-type and mutant exons. In keeping with typical estimates for NMD
efficiency (Zetoune et al., 2008), we saw ~75–80% of mutant transcript being degraded
(Figure 2D). However, no substantial variation was seen across the mutants.
Given that variability in alternative splicing or NMD could not explain the selective skeletal muscle
disarray in ttnac/c mutants, we hypothesized that this variation in severity could be due to ttnac/c
mutants interfering with the action of ttnb, although the ratio of mutant to wild-type transcript of
~20% made this an unlikely scenario. Knockdown of ttnb by morpholino disrupted ttnan/n skeletal
muscle morphology indicating that the intact skeletal muscle sarcomeric architecture in ttnan/n
mutants arose at least in part from rescue by ttnb protein (Figure 3A), although the phenotype was
not nearly as severe as that of ttnac/c mutants. To investigate a dominant negative mechanism for
Video 1. Cardiac contraction for wild-type, ttnan/n and
ttnac/c mutants. All embryos were imaged at 72 hpf.
DOI: 10.7554/eLife.09406.007
Video 2. Motility assessment for wild-type, ttnan/n and
ttnac/c mutants. All embryos were imaged at 72 hpf.
DOI: 10.7554/eLife.09406.008
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ttnac/c mutants, we performed a morpholino knockdown of ttna, targeting a splice site of an N-ter-
minal constitutive exon (exon 4), which would be expected to introduce an N-terminal frameshift on
top of the same C-terminal mutant allele. If the differences between ttnan/n and ttnac/c mutants
arose simply from inhibitory effects of the ttnac/c truncated product, then introducing an upstream
frameshift should disrupt production of the dominant negative protein product even further and
restore sarcomeric architecture. Knockdown by morpholino was effective (~78% knockdown effi-
ciency, data not shown) and the combined action of NMD and morpholino knockdown would be
expected to reduce mutant ttna protein to only ~5% of the level of ttnb protein. Nonetheless we
were unable to rescue skeletal muscle architecture in ttnac/c mutants (Figure 3B). We thus concluded
Figure 3. C-terminal ttna truncations do not act as dominant negatives. (A) Knockdown of ttnb by morpholino injection worsens skeletal muscle
sarcomeric architecture in ttnan/n mutants. Fixed skeletal muscle samples of 72 hpf ttnan1/n1 mutant embryos were analyzed by immunostaining for a–
actinin. (right) Cartoon representation of ttna and ttnb proteins, with a premature N-terminal stop codon in ttna (gold star). The purple lines indicate
morpholino disruption of the ttnb transcript. Scale bar: 10 umm. (B) Knockdown of ttna by morpholino injection does not rescue skeletal muscle
architecture in ttnac1/c1 mutants. ttnac1/c1 embyros were injected with a ttna splice-site morpholino to the exon 4-intron 4 junction at the 1–2 cell stage
and embryos were examined at 72 hpf. At this morpholino dose, knockdown efficacy was estimated at close to 80% and nearly complete cessation of
cardiac contraction was achieved in >90% of wild-type embryos (data not shown). Immunostaining for a–actinin revealed no improvement in skeletal
muscle architecture. (right) Cartoon representation of mutant ttna proteins, with a premature C-terminal stop codon (gold star). The purple lines
indicate disruption of the ttna transcript using a morpholino that is expected to introduce an N-terminal truncation upstream of the C-terminal
truncation.
DOI: 10.7554/eLife.09406.009
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Figure 4. An internal promoter at the distal I-band explains phenotypic differences between N- an C-terminal ttna mutants. (A) RNA-Seq data from
72 hpf zebrafish trunk (left) and E12.5 mouse hearts (right) depicting accumulation of reads within the intron, upstream of the orthologous exons 116
(zebrafish) and 223 (mouse). The Ttn gene is on the negative strand and so reads within the upstream intron are shown to the right of the black bar,
which indicates the position of the relevant exon. (B) Transcription from an alternative Titin promoter occurs in zebrafish, mouse, and human heart. (left)
PCR amplification using a primer in the upstream exon or an internal primer at or near the internal TSS (as determined by 5’-RACE) as forward primer
and a shared reverse primer was performed using cDNA from zebrafish, mouse and human heart. For all three species, products of the expected size
were found, supporting transcription from an internal promoter. (right) Cartoon representation of PCR amplification scheme, with exon numbering
Figure 4. continued on next page
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that ttnac/c mutants do not act as dominant negatives and that an alternative explanation was
needed.
Another possible explanation for the discrepancy in disease severity between ttnan/n and ttnac/c
mutants could be an internal promoter that produces a C-terminal isoform, which could partially res-
cue N-terminal truncations, especially in conjunction with expression of ttnb. Even though N- and C-
terminal truncating mutations would both disrupt full-length ttna, the latter would also disrupt a C-
terminal isoform while the former would not. Interestingly invertebrates, including C. elegans and D.
melanogaster, have distinct genes that encode for protein products corresponding to the N-terminal
(Z-disc and proximal I-band) or C-terminal (distal I-band and A-band and M-line) portions of Titin
(Bullard et al., 2002). The Novex-3 isoform in humans (discussed below) does in fact include only
the Z-disc and proximal I-band portions of TTN, but no isoform corresponding only to the C-terminal
portion of TTN has ever been reported in vertebrates.
Using the exon boundaries defined by ttnan3/n3 and ttnac1/c1, we examined zebrafish and mouse
cardiac and skeletal muscle transcriptomic data for patterns of reads indicating a promoter upstream
of one of the ttna exons. We noticed an accumulation of reads 5’ to exon 116 (e116, ENS-
DART00000109099) in zebrafish skeletal muscle (Figure 4A) and in the corresponding exon of
mouse heart (e223, ENSMUST00000099981, Figure 4A). We hypothesized that these reads arose
from transcription from an alternative promoter within the e115-e116 intron. 5’-RACE confirmed an
alternative transcription start site (TSS), 110 bp upstream of e116 (within the e115-e116 intron) in
zebrafish skeletal muscle, with an in-frame initiator methionine located 7 amino acids upstream of
e116. To establish conservation in mammals, we repeated 5’-RACE on adult mouse and fetal human
cardiac tissue and found a TSS in the upstream intron (257bp upstream of e223 in mouse; 256bp
upstream of the orthologous exon, e240, in humans), with a putative initiator methionine 12 amino
acids upstream of the relevant exon. Using PCR, we confirmed the presence of a multi-exonic tran-
script that includes this alternative promoter site in zebrafish, mouse, and human cardiac tissue
(Figure 4B).
We next consulted publicly available chromatin accessibility and activation data to find supporting
evidence for an internal TTN promoter at this site. DNAse-Seq is a powerful tool to identify regions
of accessible chromatin, which typically correspond to promoter or enhancer regions (Neph et al.,
2013). Examination of multiple fetal human cardiac and skeletal muscle DNA-Seq datasets revealed
a prominent peak overlying e240, the orthologous exon to e116 in humans (Figure 4C, Figure 4—
figure supplement 1). A similar peak was found in H3K4me3 Chip-Seq data, a mark for active pro-
moters (Zhou et al., 2010), from skeletal muscle and cardiac tissue (Figure 4C, Figure 4—figure
supplement 1). Unbiased epigenetic data thus provides additional strong support for an internal
Figure 4. Continued
according to zebrafish transcript. The zebrafish 5’ UTR is shorter than that of mouse and human. (C) (left) H3K4me3 ChIP-Seq data from human fetal leg
muscle (GEO Accession GSM1058781), indicating an active promoter overlies exon 240, which is orthologous to exon 116 in zebrafish. The peak at the
far right of the figure represents the conventional human TTN promoter. (right) DNAse-Seq data from human fetal heart (GEO Accession GSM665830)
indicates highly accessible chromatin overlying exon 240, which typically demarcate enhancers or promoters (Neph et al., 2013). The accessible
chromatin peak at the far right is the conventional TTN promoter. The gold triangle in both panels indicates the genomic position of the human
internal promoter TSS identified through 5’-RACE. (D) Phenotypic divergence in skeletal myopathy in ttna truncations occurs at the exons flanking the
alternative promoter. Cas9 protein and high dose gRNAs corresponding to exon 115 or exon 116 were injected into 1 cell embryos. At 72 hpf, embryos
with complete or near complete cessation of cardiac contraction were collected and immunostained for a–actinin to assess skeletal muscle architecture.
(E) An ATG morpholino targeting the intronic region upstream of the novel initiator methionine is sufficient to create skeletal muscle disarray on a
ttnan3/n3 background. 1–2 cell embryos from a ttnan3/wt cross were injected with an intronic morpholino and ttnan3/n3 homozygotes immunostained for
a–actinin to assess sarcomere architecture in the skeletal muscle. No skeletal muscle disarray was seen in wild-type fish injected with the internal ATG
morpholino (data not shown).
DOI: 10.7554/eLife.09406.010
The following figure supplements are available for Figure 4:
Figure supplement 1. H3K4me3 Chip-Seq analysis of human fetal muscle (top, GEO Accession GSM1160200) and DNAse-Seq analysis of fetal human
heart (bottom, GEO Accession GSM665817) identifies an internal chromatin accessible peak overlying the alternative TTN promoter.
DOI: 10.7554/eLife.09406.011
Figure supplement 2. The transition between mild and severe skeletal phenotypes occurs at intron 115, the site of the alternative promoter.
DOI: 10.7554/eLife.09406.012
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promoter. For convenience, and as a counterpart to the N-terminal Novex-3 isoform, we hereafter
refer to this C-terminal Titin isoform as the Cronos isoform.
If a protein product arising from the ttna internal promoter ameliorates disease severity in
ttnan/n but not ttnac/c mutants, we should be able to pinpoint the phenotypic transition at e116 –
i.e. truncation mutants N-terminal to e116 should have mild phenotypes while those at or C-termi-
nal to e116 should have severe phenotypes. Interestingly, the corresponding human genomic posi-
tion (the e239-e240 intron in ENST00000589042) represents the exact transition point for where
disease severity markedly increases in DCM TTN truncation patients (Figure 1A). We used high
dose guide RNA (gRNA) and Cas9 protein injections to exons 113, 114, 115, 116, and 122 and
examined cardiac and skeletal muscle architecture and function in the resulting fish, focusing on
embryos with nearly complete cessation of cardiac beating, as these would be expected to have a
high likelihood of homozygous genomic disruption (given that only homozygote and not heterozy-
gote ttnan/n or ttnac/c mutants have a cardiac phenotype). As expected, e113, e114 and e115 F0
mutants showed intact skeletal muscle architecture while e116 and e122 mutants had severe skele-
tal muscle disruption (Figure 4D, Figure 4—
figure supplement 2). To confirm that the Cro-
nos isoform protein product was actually trans-
lated, we used agarose protein electrophoresis
and found that a higher mobility (smaller size)
protein product was indeed found in wild-type
and ttnan/n mutants but not in ttnac/c mutants
(Figure 5A). Finally, a translation start site mor-
pholino targeted upstream of the actual alter-
native initiator methionine (and 38 nucleotides
upstream of the intron-exon junction) was suffi-
cient to completely impair motility and disrupt
skeletal muscle architecture in the ttnan3/n3
Figure 5. Premature termination codons in ttna differentially affect the levels of Cronos and full-length ttna depending on mutation location. (A) 1.0%
agarose gel reveals higher molecular weight bands corresponding to different splice isoforms of ttnb (all fish) and ttna (wild-type only). The arrow
represents Cronos isoform of ttna, which is absent in C-terminal truncation mutants and in zebrafish treated with an ATG morpholino against this
isoform. Ttna and ttnb expression results in a complex distribution of splice isoforms, whose identity and composition vary over early development
(Steffen et al., 2007). (B) NMD results in a high ratio of Cronos to full-length ttna transcript levels in N-terminal but not C-terminal truncation mutants.
Quantitative real-time PCR was used to estimate relative levels of the Cronos and full-length ttna trancripts for wild-type and mutant embryos. No
efficiency difference was seen for the corresponding primer pairs.
DOI: 10.7554/eLife.09406.013
Video 3. Motility for wild-type and ttnan/n mutants
injected with internal promoter ATG morpholino
DOI: 10.7554/eLife.09406.014
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mutant (Figure 4E, Video 3), further supporting the hypothesis that the Cronos product can res-
cue skeletal muscle architecture in ttnan/n mutants. No obvious impact of the morpholino on alter-
native splicing of neighboring exons was seen (data not shown).
Given that NMD substantially reduces the levels of ttna transcripts with premature termination
codons (Figure 2D), we reasoned that we should be able to distinguish N- and C-terminal truncation
mutants by the ratio of Cronos to full-length transcript. In ttnan/n mutants, which would degrade full-
Figure 6. Tissue and developmental profile of Cronos and ttna expression in zebrafish and mouse heart and skeletal muscle. (A) In situ hybridization at
72 hrpf (left) and 24 and 48 hpf (right) reveal prominent expression of both Cronos and full length ttna isoforms in zebrafish somites. In contrast, Cronos
expression in developing zebrafish heart (arrow) is at low levels. (B) Quantitative PCR estimates of the ratio of Cronos to full-length ttna reveals
prominent expression in developing zebrafish skeletal muscle, but markedly reduced expression in developing heart and in adult heart and skeletal
muscle. (C) Quantitative PCR estimates of the ratio of Cronos to full-length Ttn reveals prominent expression in developing mouse hearts, which
diminishes through development. Skeletal muscle Cronos expression is comparable in early postnatal mouse, but diminished in adulthood and varies
by skeletal muscle bed. EDL = extensor digitorum longus. LV/RV = left/right ventricle.
DOI: 10.7554/eLife.09406.015
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length ttna but not Cronos, we would anticipate a higher Cronos:full-length ratio than in ttnac/c
mutants mutants, which should degrade both transcripts approximately equally. As expected, we
see a much higher ratio of Cronos:full-length transcript levels in ttnan/n mutants than in ttnac/c
mutants (Figure 5B).
We next surveyed the expression levels of Cronos in cardiac and skeletal muscle in zebrafish at
different developmental stages using both in situ hybridization (Figure 6A) and real-time PCR
(Figure 6B). Cronos is expressed at high levels in zebrafish skeletal muscle during development
(~2:1 ratio of Cronos to full-length ttna), but drops off sharply during adulthood (~1:70 ratio).
Although the Cronos expression in zebrafish heart also appears to be developmentally regulated, it
is much lower than in skeletal muscle, with a ~1:5 ratio at 72 hpf and 1:30 ratio in adulthood. This
low cardiac Cronos expression (coupled with a minor role of ttnb in zebrafish hearts) is a likely reason
for the severe and indistinguishable cardiac sarcomere disruption in ttnan/n and ttnac/c mutants.
Given that the primary observation that motivated this work was variation in phenotypic severity
in cardiomyopathy patients, we next looked to see if there was appreciable Cronos expression in
mammalian hearts. We found that Cronos levels were much higher in developing mouse hearts than
in zebrafish, with nearly equal transcript levels of Cronos and full-length Ttn (Figure 6C) at embry-
onic day 12.5. Thereafter mouse cardiac expression of Cronos decreases to ~20–30% of full-length
Titin. Skeletal muscle expression varies across development and in different muscle beds with a 1:5
ratio in mouse hindlimb at P2, and between 1:16 and ~1:1000 ratios in adult extensor digitorum lon-
gus (fast-twitch) and soleus (slow-twitch) muscle, respectively.
Although our zebrafish work explains why a milder phenotype would be expected in individuals
with truncation mutants upstream of the alternate promoter, it does not answer whether such N-ter-
minal truncations would still result in deleterious manifestations in heterozygote patients. Specifi-
cally, an open question remains whether all TTN truncations lead to cardiac or skeletal muscle
phenotypes, or conversely, do any TTN truncations lack cardiac or skeletal muscle consequences. In
a disease such as dilated cardiomyopathy, with a variable age of onset, it can be challenging to
derive general conclusions from observational data of control subjects, many of whom are young or
middle-aged. Furthermore, self-reports of ‘health’ may not reveal limitations in an individual’s ability
to attain full exercise potential, especially with aging.
To assess whether any TTN truncations are compatible with a high degree of cardiovascular fit-
ness throughout life, we turned to a population genetics approach, and sequenced the complete
TTN exome (as well as that of 104 other Mendelian cardiac disease genes, Supplementary file 1A)
in 199 competitive senior athletes who entered as contestants in the Huntsman World Senior Games
(median age 73, Table 2). We compared the frequency and distribution of TTN truncation muta-
tions to those found in unselected controls and healthy volunteers from a recent sequencing study
(CTLlit) (Roberts et al., 2015). The overall rate of TTN truncations did not differ between senior ath-
letes and CTLlit (1.5 vs 1.2%, p = 0.91). However, the distribution of TTN truncations differed signifi-
cantly between groups (Figure 7, Figure 7—figure supplement 1): TTN truncations in senior
athletes mapped exclusively to the extreme C-terminal exon of the rare Novex-3 isoform
(Bang et al., 2001), at a nearly 8-fold higher rate than CTLlit (p = 0.003). This exon is found only in
the Novex-3 isoform, which is expressed at low levels in the human heart (<10% of the levels of
major TTN isoforms [Roberts et al., 2015]), and we would thus expect truncations in this exon would
have little effect on TTN function. We next analyzed the ratio of mutants up- and downstream of
Cronos in affected DCM patients, literature controls and senior athletes (Figure 7). As expected, in
end-stage DCM we observed a much higher rate of mutants C-terminal to Cronos than N-terminal
Table 2. Demographic characteristics of 199 senior athletes genotyped by capture-based targeted
sequencing for this study.
Number 199
Age 73 (IQR 68-77)
Sex 60% Male
Race 97% European American
Sports Track and field, volleyball, cycling, softball, marathon, …
DOI: 10.7554/eLife.09406.016
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(30:1), followed by unselected DCM (37:11), literature controls (6:11, 2:2, 10:7 for FHS, healthy vol-
unteers and JHS) and senior athletes (0:3).
Discussion
Loss of function experiments across a number of systems have demonstrated Titin’s importance in
diverse aspects of sarcomere development and function, including the ordered assembly of sarco-
meric constituents (Xu et al., 2002; van der Ven et al., 2000), cardiomyocyte systolic (Hinson et al.,
2015) and diastolic function (Radke et al., 2007), and resistance to neurohormonal and vasocon-
strictor stresses (Gramlich et al., 2009). Our work further contributes the discovery of a conserved
internal promoter in TTN, whose protein product is essential for skeletal muscle sarcomere develop-
ment in zebrafish. The Cronos promoter is prominently expressed in developing mouse heart, and
its location coincides strikingly with the position of TTN truncations in patients with the most severe
forms of dilated cardiomyopathy. Our working model is that disruption of both the full-length TTN
and Cronos protein products results in more severe disease than disruption of the full-length prod-
uct alone.
Throughout this work, we have focused on skeletal muscle architecture and function in zebrafish
ttna homozygote mutants, given that this tissue demonstrates a sharp and rapidly developing phe-
notypic distinction between N- and C-terminal Titin truncations. The early onset of this unambiguous
phenotypic difference combined with the ease of genetic and transcriptomic manipulation using
Figure 7. TTN truncations are found preferentially upstream of the Cronos promoter in controls but downstream
of Cronos in DCM cases. Ratio of the number of truncating mutations found C-terminal to the position of the
Cronos promoter to those found N-terminal, in DCM cases and controls derived from the literature
(Roberts et al., 2015) and in senior athletes.
DOI: 10.7554/eLife.09406.017
The following figure supplements are available for Figure 7:
Figure supplement 1. Mapping of TTN truncation mutations seen in literature cases and controls(Roberts et al.,
2015) and senior athletes onto a schematic of the TTN meta-transcript.
DOI: 10.7554/eLife.09406.018
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CRISPR/Cas9 and morpholino technology allowed efficient mapping of the novel Cronos internal
promoter as well as testing of alternative mechanistic hypotheses for this phenomenon. Nonetheless,
implicit in our work is the assumption that findings from zebrafish skeletal muscle sarcomere devel-
opment in ttna homozygote mutants (albeit with the paralogous ttnb present for rescue) are relevant
towards understanding disease development in humans with TTN mutations. Prominent differences
between these systems must be noted. With the exception of certain childhood-onset forms of skel-
etal and cardiac myopathy arising from homozygous TTN truncations (Carmignac et al., 2007; Cey-
han-Birsoy et al., 2013), the mode of inheritance in TTN truncation mutation patients is
heterozygous with marked variable expressivity and incomplete penetrance (Herman et al., 2012;
Roberts et al., 2015; Itoh-Satoh et al., 2002; Norton et al., 2013; van Spaendonck-Zwarts et al.,
2014). Moreover, disease onset usually occurs in adulthood. Such an inheritance pattern is typical of
many of the familial forms of cardiomyopathy, and is believed to imply additional modifying effects,
potentially from diverse sources as autoimmunity and viral infection as well as contributions from
additional genetic variants (Mrh et al., 2015). Nonetheless, taking all of our results together, we find
it a highly plausible explanation that a superimposed deficiency in expression of the Cronos protein
product would result in the more severe forms of human cardiac disease seen in DCM patients with
C-terminal TTN truncations.
With these limitations noted, our results have two clinical implications for titinopathy patients.
Firstly, by precisely mapping the location of the alternate promoter to the e239-e240 intron in
humans, we are in a better position to give mutation-specific guidance to TTN truncation patients
regarding the potential severity of their disease, with the caveat that additional factors (genetic and
environmental) also modulate phenotypic severity. Along these lines, given the overlapping distribu-
tion of mutations in unselected cases and controls, it is unlikely that highly accurate patient progno-
ses would be realized from genotype information alone (Figure 7—figure supplement 1), although
there does appear to be nearly complete separation of mutation distribution for the more extreme
phenotypes (end-stage DCM and senior athletes). Secondly, our work implies that strategies that
augment activity of the internal TTN promoter and levels of the Cronos isoform might provide thera-
peutic benefit in TTN truncation patients, although it is unclear whether there is a restricted develop-
mental window where this might be possible.
In addition to clinical ramifications, our work may shed light on a long-standing mystery regarding
sarcomeric architecture. Electron microscopy reconstructions of serial sections of skeletal muscle
dating back over 50 years presented a puzzle: the thin/thick filament arrangement in the sarcomere
alters its geometry, progressing from a tetragonal lattice arrangement at the Z-band to a trigonal
arrangement in the A-band (Pringle, 1968), with the transition taking place near the I-A junction
(Traeger et al., 1983). The implication for TTN would be that there would be a resulting increase in
the copies of TTN protein, with four at the Z-band and six at the A-band and M-line
(Liversage et al., 2001), which is difficult to reconcile with the fact that a single TTN molecule spans
the entire length, from Z-band to M-line. Our data provides a simple explanation for this observa-
tion, with the Cronos protein product selectively increasing copies of TTN at the distal I-band, A-
band and M-line. Our work also proposes an alternative explanation for the consistently observed
‘T2’ band on protein gels, which migrates at the expected molecular weight of Cronos. This has
invariably been labeled a C-terminal degradation product, as it reacts with A-band antibodies
(Opitz et al., 2004). However, in keeping with Cronos expression patterns in development, the T2
band was prominently seen in developing mouse (Lahmers et al., 2004) and rat hearts (Opitz et al.,
2004), but was markedly reduced in adulthood. It is possible that, at least in some situations, T2 and
Cronos represent the same isoform.
These results also raise a number of questions related to the function of the Cronos isoform.
Given its more marked expression in early development, is it important only for the initial sarcomero-
genesis or in subsequent aspects of muscle function? Is it likely to be reactivated under stress? And
how fast does it turn over compared to full-length TTN? Models with selective disruption and tag-
ging of this isoform should begin to answer these questions. Finally, it is possible that unrecognized
internal promoters influence disease severity in truncating mutations of other genes. It is likely a
more nuanced diagnostic and prognostic interpretation of truncating mutations will be needed.
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Materials and methods
sgRNA design, cloning, and in vitro transcription
sgRNA’s were designed using an in-house Python script, which scans genomic sequences for 23 bp
sequences with a terminal NGG (PAM sequence), and prioritizes a GG at the 5’ end because of the
use of T7 RNA polymerase for gRNA synthesis. All sgRNA’s had only a single genome match. Oligo-
nucleotides corresponding to the sgRNA sequence were annealed and then cloned into vector
DR274 (Addgene plasmid 42250) as previously described (Hwang et al., 2013). For sgRNA synthe-
sis, 100 ng of plasmid template was used in a T7 in vitro transcription reaction (MAXIscript T7, Life
Technologies, Carlsbad, CA, AM1312M). RNA products were digested with DNAse I and purified by
column (RNA Clean and Concentrator, Zymo Research, Irvine, CA, R1016).
Cas9 induced genomic cleavage and genotyping
Recombinant Cas9 was prepared as previously described (Jinek et al., 2012). A mixture of recombi-
nant Cas9 (0.5 ug/uL) and sgRNA 5-(40 ng/uL) was prepared and injected (1 nL total volume) into
one-cell stage embryos (Ekwill strain). Cutting efficiency was assessed by pooling injected embryos
at 24 hr post fertilization (hpf), extracting genomic DNA, amplifying the genomic targeted region by
PCR (see Supplementary file 1B for primers), and using the Cel1 assay (Oleykowski et al., 1998) to
detect evidence of targeted mutations.
To pinpoint the exon at which skeletal muscle disarray occurs, recombinant Cas9 and high dose
gRNAs (100 ng/uL) corresponding to exons 113, 114, 115, 116, 122 and the predicted start codon
for the alternative promoter were each injected into ~120 one-cell stage embryos. Given that homo-
zygotes of either N- or C-terminal truncation mutants of ttna cause cessation of cardiac contraction,
we focused our attention on those fish with obvious contractile defects and further phenotyped
these through motility assays and immunohistochemistry (see below). For each of the targeted
exons, 10 embryos with cessation of contraction were analyzed by immunostaining.
Husbandry and genotyping
Zebrafish founders were outcrossed onto the Ekwill background, and subsequent progeny out-
crossed again. F2 founders were then in-crossed to obtain F3 generation homozygote mutants,
which were used for phenotypic and genomic analysis. Genotyping was performed using the Cel1
assay (Oleykowski et al., 1998) and/or allele-specific PCR analysis (Gaudet et al., 2007).
Immunohistochemistry
Embryos were fixed and stained using standard procedures (Deo et al., 2014). Briefly, anesthetized
embryos at 3 dpf were fixed in 4% paraformaldehyde (PFA) for 12 hr. Fixed tissue was washed in
PBS + 0.1% Triton X-100 (PBST), permeabilized with 10 ug/mL proteinase K in PBST, and then
refixed with 4% PFA for 20 min after which it was subjected to standard blocking and antibody incu-
bations. Primary antibodies used were mouse anti-human alpha-actinin (Life Technologies, MA1-
22863, 1:500 dilution) and titin T11 (Sigma-Aldrich, St. Louis, MO, T9030, 1:100) and T12 (1:10, a
generous gift from Elisabeth Ehler and Dieter Fuerst). The secondary antibody was donkey-anti-
mouse conjugated to an Alexa-488 fluorophore (Life Technologies, R37114, 1:500).
Imaging and data analysis
Videos at 100–250 frame per second of beating hearts were taken from live 72 hr post-fertilization
(hpf) embryos using an Axiozoom V16 Stereo (Carl Zeiss, Oberkochen, Germany) with a 10 objec-
tive lens and an Orca Flash 4.0T high-speed digital camera (Hamamatsu Photonics, Hamamatsu City,
Shizuoka, Japan). Confocal images were collected on a Leica TCS SP5 with a 63x objective lens. To
assess motility, embryos were tapped gently with a whisker.
Morpholino knockdown
ATG- and splice-blocking morpholinos to ttna (conventional and alternative promoter) and ttnb were
designed with the help of Gene Tools staff (http://www.gene-tools.com/). Morpholino sequences
were TAA ATG TTG GAG CTT GCG TTG ACA T (ATG) and AAT TAC CTT TGA TTG TGA CTT TGG
T (Seeley et al., 2007) for ttnb and CCT GTG TTG TCA TGG TGG AAG GCA C (conventional ATG),
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GTT CCA GGA GAC ACA GGT AAT CCC T (internal ATG) and TGC AAC TGA TAC TCA CCT TCT
CCA C (exon4-intron4 junction) for ttna. Morpholinos were re-suspended in sterile water to a con-
centration of 1 mM and diluted to working concentration in sterilized water. Male and female wild-
type adult zebrafish were housed and embryos bred using standard protocols (Westerfield, 1993).
Morpholinos were introduced into the zebrafish yolk via microinjection at no later than the two-cell
developmental stage. Injected embryos were then kept at 28.5˚C in E3 solution (5 mM NaCl, 0.17
mM KCl, 0.33 mM CaCl2, 0.33 mM MgSO4). The conventional promoter ttna/ttnb ATG-morpholinos
were highly toxic, even at low concentrations. We thus focused on using the ttna and ttnb splice-
blocking morpholino’s as well as the internal promoter ttna ATG morpholino at working concentra-
tions of 5 ng/nl. To further reduce toxicity, we co-injected the ttna splice-blocking morpholino with a
previously described p53 morpholino at 5 ng/nl (Robu et al., 2007). In terms of sample size, we typi-
cally injected 100–150 embryos for every experiment.
Zebrafish RNA-sequencing and analysis
High depth RNA-Sequencing of wild-type embryonic hearts was first performed to select constitutive
exons for gRNA targeting. Embryo heart purification was carried out as described (Geoffrey Burns
and Macrae, 2006). Briefly, 300–400 embryos of Tg (cmcl2-GFP) at 3 dpf were pooled for a single
sequencing experiment. Embryo Dissociation Medium (EDM) was freshly prepared using Leibovitz’s
L-15 Medium (Life Technologies, 11415–064) containing 10% FBS (Sigma, F-2442), and kept ice-cold
prior to use. After washes with EDM, embryos in 1 ml of EDM were drawn to a 3 ml syringe with
19G needle and expelled back to the tube for 30 times. Large embryo fragments were filtered out
using a 100 um filter, and the filter was washed several times with more EDM. The flow-through was
collected in a 60-mm glass petri dish on ice, and then applied to a 40 um filter. The filter was
inverted and the retained fragments including hearts were washed off into a glass dish with 5x1ml
EDM. GFP + hearts were sorted under fluorescent light using a Leica (Leica Camera, Wetzar, Ger-
many) M205 FA fluorescence microscope. Trizol-extracted RNA was purified by column (RNA Clean
and Concentrator, Zymo Research, R1016). Sequencing libraries were prepared using the SureSelect
Strand Specific RNA-Seq kit (Agilent Technologies, Santa Clara, CA, G9691A), following the manu-
facturer’s instructions. 101 bp paired end sequencing was performed on a HiSeq 2500 sequencer
(Illumina, San Diego, CA).
For analysis of splicing of ttna mutants, hearts and skeletal muscle (trunk) were isolated from ttna
mutant and wild-type zebrafish embryos (72 hrpf) and adults using manual dissection after euthana-
sia. Pooled hearts and skeletal muscle from 10 fish were used for subsequent library preparation.
The tissue was lysed in Trizol (Life Technologies). RNA was recovered from the aqueous phase and
purified purified by column (RNA Clean and Concentrator, Zymo Research, R1016) according to
manufacturer’s protocol. cDNA was prepared using the Ovation RNA-Seq System V2 (NuGEN Tech-
nologies) with sonication into 200bp fragments using an M220 sonicator (Covaris, Woburn, MA).
Sequencing libraries were prepared using the Ovation Ultralow Ultralow DR Library System (NuGEN
Technologies, San Carlos, CA). 101 bp single end sequencing was performed on a HiSeq 2500
sequencer in rapid run mode, with 7 samples per lane of the flow cell.
Reads were mapped to the dr7 build of the zebrafish genome using TopHat (Trapnell et al.,
2009). Samples were normalized using the edgeR package (Robinson et al., 2010), with trimmed
mean of M values (TMM) normalization. Percent spliced in estimates were made using in-house
Python scripts implementing previously published methods of splice isoform quantification using
exon-exon junction reads (Pervouchine et al., 2013), which avoid the estimation difficulties arising
from non-uniform read coverage of exons (Kakaradov et al., 2012).
Mouse RNA-sequencing and analysis
The heart from an E12.5 129X1/SvJ x C57BL/6 cross mouse was disrupted in Trizol with plastic pestle
and passed through QIAshredder (Qiagen, Hilden, Germany, 79654) for homogenization. RNA was
isolated from Trizol using a 1:1 mixture with 70% ETOH followed by column purification and DNase
treatment (RNeasy Mini kit, Qiagen, 74104). The cDNA was generated and amplified using the Ova-
tion RNA-Seq System V2 (NuGEN Technologies) and the library was prepared using the Ovation
Ultralow Ultralow DR Library System (NuGEN Technologies). 101 bp single end sequencing was
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performed on a HiSeq 2500 sequencer. Reads were mapped to the mm9 build of the mouse
genome using TopHat (Trapnell et al., 2009).
Nonsense-mediated decay rate estimates
To estimate nonsense-mediated decay (NMD) rates, we evaluated allelic imbalance in heterozygote
embryos. For each mutant of interest, total RNA was extracted from three heterozygote embryos.
Primers, designed to span at least one exon-exon junction, were used to amplify ~100 bp surround-
ing the mutation of interest. For each embryo, 2 independent PCR reactions - each with 10 amplifi-
cation cycles - was performed. Next generation sequencing libraries were prepared using the
NEBNext Ultra kit (New England Biolabs, Ipswich, MA, E7370S) with 10 cycles post-amplification.
Samples were assessed by 100 bp single end sequencing on a MiSeq instrument (Illumina). The ratio
of mutant to wild-type reads was used as a measure of allelic imbalance. For each mutation,
between 600 and 10,000 reads were used for ratio estimates.
Quantitative real-time PCR to assess ratio of Cronos to full-length ttna/
Ttn in zebrafish and mouse
Forward primers mapping to either e115 or the Cronos isoform was used in combination with a
reverse primer spanning the e116-e117 exon-exon junction. Similar primers were designed to detect
Cronos vs. full-length Ttn levels in mouse. Standard curves using a cloned PCR product were used to
compare relative primer efficiencies (data not shown). Quantitative real time-PCR analyses were car-
ried out with cDNA templates using SensiFast SYBR green (Bioline Reagents, London, UK) on the
CFX384 Real Time PCR system (BioRAD, Hercules, CA) (Heredia et al., 2013).
Zebrafish samples for qPCR consisted of embryonic and adult hearts and trunk muscle, and were
isolated as described above. Mouse heart and skeletal muscle samples were taken from C57BL/6 or
CD1 mice purchased from Jackson laboratory. All mice were euthanized by CO2 inhalation and cer-
vical dislocation prior to surgical dissection of relevant tissues.
Human RNA-Sequencing analysis
We downloaded fastq format files for DCM patients and healthy controls corresponding to GEO
Accessions GSM1380718, GSM1380719, GSM1380722, and GSM1380723. Reads were mapped to
the hg19 build of the human genome using TopHat (Trapnell et al., 2009). PSI values were com-
puted as described above.
Use of Publicly Available DNAse-Seq and ChIP-Seq data
We downloaded bed format files corresponding to GEO Accessions GSM665817 (fetal heart),
GSM530661 (fetal heart), GSM665817 (fetal heart), GSM665824 (fetal heart), GSM665830 (fetal
heart), GSM701533 (fetal trunk), GSM772735 (fetal heart), GSM906406 (left ventricle), GSM1027322
(pediatric heart), GSM1058781 (fetal leg), GSM1160200 (fetal trunk), and GSM530654 (fetal heart).
Depth of coverage analysis was performed using in-house R scripts and data plotted using the
ggplot2 package (Wickham, 2009).
5’ RACE
5’ RACE was performed using published protocols (Picelli et al., 2014; Matz et al., 1999). An oligo-
nucleotide for template switching (TSO, Univ_UMI_RACE, Supplementary file 1B) was purchased
from Exiqon (Woburn, MA). Total RNA was obtained from three sources. Zebrafish RNA was isolated
from zebrafish skeletal muscle, as described above. Mouse RNA was isolated from cardiac tissue of
a euthanized adult mouse (C57BL/6) using manual dissection of the heart followed by tissue homog-
enization, Trizol extraction, and RNA column purification (RNA Clean and Concentrator, Zymo
Research, R1016). Fetal human heart (31 week old, male) RNA was purchased
(BioChain Institute, Newark, CA, R1244122-50). First strand synthesis was performed using a TTN
gene-specific primer (Supplementary file 1B) and the TSO, with SmartScribe reverse transcriptase
(Clontech, Mountain View, CA, 639536) and with added SUPERase In RNAse inhibitor (Life Technolo-
gies, AM2694). Uracil-DNA Glycosylase (New England Biolabs, M0280S) was used to degrade any
remaining TSO according to manufacturer’s instructions. PCR amplification of the resulting cDNA
was performed using a nested gene-specific primer (Supplementary file 1B) and a universal 5’
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primer (Supplementary file 1B) with a touch-down annealing temperature protocol. PCR products
were gel purified (Zymo Research, D4001), blunt-end cloned using the pGEM-T Easy Vector system
(Promega, Madison, WI, A12360) and analyzed by Sanger sequencing.
In situ hybridization
Whole-mount in situ hybridization with digoxigenin-labeled mRNA antisense probes to Cronos and
ttna was performed as previously described (Thisse and Thisse, 2008). For Cronos, an 89nt digoxi-
genin-labeled riboprobe unique to this isoform was hybridized at 60˚C. For ttna, a 453nt riboprobe
corresponding to a constitutive region was hybridized at 68˚C. In both cases embryos were devel-
oped in BM purple (11442074001, Sigma-Aldrich).
Protein electrophoresis
Briefly, euthanized zebrafish embryos were Dounce homogenized in lysis buffer (500 mM Tris pH 7.4
150 mmM NaCl, 1% NP-40, 1 mM PMSF, 1x protease inhibitor cocktail [Sigma-Aldrich]) on ice and
centrifuged at 14,000 g for 10 min at 4C. The denaturing/loading buffer (8 M urea, 2 M thiourea, 3%
SDS, 75 mM DTT, 0.1% bromophenol blue, 0.05% Tris-HCl pH 6.8) was mixed with the lysate at a
4:1 ratio and the resulting sample denatured at 60˚C for 15 min. Electrophoresis was performed
using a denaturing 1% agarose gel at 15mA for 3–6 hr (3 hr for Myosin and 6 hr for Titin) on a Hoe-
fer (Holliston, MA) SE 600 gel unit (Steffen, et al., 2007; Warren, et al., 2003). Gels were fixed for
at least 1 hr after running, briefly washed in water and vacuum dried at 40C overnight. The following
day, the gel was rehydrated and stained with SYPRO Ruby protein gel stain (S4942, Sigma-Aldrich)
according to manufacturer’s instructions.
Senior athlete recruitment
199 healthy senior athletes with no prior history of cardiac disease were recruited between 2004 and
2012 at the Huntsman World Senior Games (held in St George, Utah). DNA from whole blood was
extracted using the Gentra Puregene DNA isolation kit (Qiagen, 158445).
Targeted capture-based sequencing and variant calling
Targeted capture and variant calling were performed as previously described (Deo, et al., 2014).
Briefly, NimbleGen’s SeqCap EZ Choice technology was used to construct oligonucleotide probes
complementary to the exons (Ensembl GRCh37) of 160 genes involved or predicted to be involved
in Mendelian forms of cardiac disease (Supplementary file 1A). Genomic DNA libraries were
sheared by sonication on a M220 sonicator (Covaris), hybrdized to the capture probes, and libraries
prepared from the captured material using the Kapa Biosystems (Wilmington, MA) Library Prepara-
tion Kit. Libraries were sequenced on an Illumina HiSeq 2500 sequencer with multiplexing of 24 sam-
ples per lane. Assembly was performed using bwa (Li and Durbin, 2009) and variants called using
the GATK (McKenna, et al., 2010). Median coverage was 455-fold with 99.6% of exons found to be
callable for the major cardiac N2BA isoform (ENST00000591111)and 98.4% callable for the Inferred
Complete isoform (ENST00000589042). Seven samples were captured with a prior cardiomyopathy
gene panel of 116 genes (Deo, et al., 2014).
Coding sequence mutations resulting in a premature nonsense codon or frame-shift were consid-
ered to be truncating mutations. For mutations of canonical (-1/-2) splice acceptor variants, which
would most likely result in exon skipping, we further required that the downstream exon was not in
the same codon phase as the skipped exon, as this would fail to produce a frame-shift and thus not
result in a truncation (such a situation is common in the I-band). Likewise, for mutations of canonical
splice donor variants (+1/+2), which we predicted would result in intron read-through, we performed
in silico translation of the resulting retained intron to ensure that a premature truncation was
observed (this was not always the case, especially for the I-band).
Statistical analysis
All statistical analysis was performed in R (3.1.1). A difference in proportion test was applied to the
prevalence of TTN truncations in senior athletes vs. literature controls, as well as the fraction of TTN
truncations that map to the Novex-3 exon.
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